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Background: Neurofeedback (NFB) attempts to alter the brain’s electrophysiological
activity and has shown potential as a pain management technique. Existing
studies, however, often lack appropriate control groups or fail to assess whether
electrophysiological activity has been successfully regulated. The current study is a
randomized controlled trial comparing changes in brain activity and pain during NFB
with those of a sham-control group.
Methods: An experimental pain paradigm in healthy participants was used to
provide optimal control of pain sensation. Twenty four healthy participants were blind
randomized to receive either 10 × NFB (with real EEG feedback) or 10 × sham (with
false EEG feedback) sessions during noxious cold stimulation. Prior to actual NFB
training, training protocols were individually determined for each participant based on a
comparison of an initial 32-channel qEEG assessment administered at both baseline and
during an experimental pain task. Each individual protocol was based on the electrode
site and frequency band that showed the greatest change in amplitude during pain, with
alpha or theta up-regulation at various electrode sites (especially Pz) the most common
protocols chosen. During the NFB sessions themselves, pain was assessed at multiple
times during each session on a 0–10 rating scale, and ANOVA was used to examine
changes in pain ratings and EEG amplitude both across and during sessions for both
NFB and sham groups.
Results: For pain, ANOVA trend analysis found a significant general linear decrease in
pain across the 10 sessions (p = 0.015). However, no significant main or interaction
effects of group were observed suggesting decreases in pain occurred independently of
NFB. For EEG, there was a significant During Session X Group interaction (p = 0.004),
which indicated that EEG amplitude at the training site was significantly closer to the
target amplitude for the NFB compared to the sham group during painful stimulation,
but this was only the case at the beginning of the cold task.
Conclusion: While these results must be interpreted within the context of an
experimental pain model, they underline the importance of including an appropriate
comparison group to avoid attributing naturally occurring changes to therapeutic effects.
Keywords: EEG-biofeedback, neurofeedback, experimental pain in humans, neuromodulation, sham-controlled
design, acute pain, pain, sham-controlled
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INTRODUCTION
Chronic pain is one of the leading causes of disability (Van
Hecke et al., 2013) and negatively impacts wellbeing, sleep, and
physical health (Hadi et al., 2019; Murray et al., 2020), as well
as costing billions in health care and lost work productivity
(American Geriatrics Society Panel on the Pharmacological
Management of Persistent Pain in Older Persons, 2009; Langley
et al., 2010; Abdulla et al., 2013; Gaskin et al., 2017; Saxen and
Rosenquist, 2020). Pain can also persist well after any physical
injury has healed suggesting the central nervous system may
play a significant role in the experience and maintenance of
pain. Although the cortical signature of pain is complex, reliable
evidence suggests involvement of a neuromatrix of cortical
pathways (Melzack, 1999, 2001, 2005; Fitzgerald, 2020) including
the anterior cingulate, prefrontal cortex, insular cortex, and
primary and secondary cortices (Casey, 1980; Brooks and Tracey,
2005). These pathways may be mediated by several physiological
(Apkarian et al., 2005) and psychological components (Wall et al.,
1994; Thompson et al., 2012; Herbert et al., 2014; Riva et al., 2014;
Dave et al., 2015). In theory, if the activity of the brain structures
involved in pain processing can be regulated, this could in turn
influence our experience of pain (Ros et al., 2010, 2013). This
has led to an increased interest in novel interventions for pain
management, such as neurofeedback (NFB).
NFB involves the real-time feedback of a person’s cortical
activity by translating an EEG signal measured at the scalp to
a changing audio or visual display (e.g., moving bars) in line
with changes in the EEG. The basic aim of NFB is to provide
a reward [e.g., auditory (music, chime), visual (point, token)]
for a change in EEG activity that it is believed to be associated
with a positive emotional or behavioral change, in line with basic
principles of instrumental conditioning (Schabus et al., 2017).
However, a recent review by Enriquez-Geppert et al. (2013)
studied the role of NFB in the improvement of executive function
(EF). Executive function is an important function that mediates
learning, which highlights the link between both behavioral and
cognitive elements involved in NFB training, and that there
may be multiple factors that drive treatment efficacy (Enriquez-
Geppert et al., 2013; Ros et al., 2020). There is a debate to
the extent of which NFB can alter brain activity, and the exact
mechanisms to how it operates (Gruzelier, 2014a,b; Ros et al.,
2020), and reinforces the importance to conduct controlled
studies in order to evaluate efficacy (Thibault et al., 2017).
Several studies have generated some promising findings
supporting the potential of NFB for pain management (Roy et al.,
2020). Some of the earliest studies were case studies (Sime, 2004;
Kayiran et al., 2007). Sime (2004) studied a single female patient
suffering from trigeminal neuralgia. It was concluded that the
patient had experienced a large reduction in pain to the extent she
canceled her planned neurosurgery, and even reduced her use of
prescribed analgesic. Kayiran et al. (2007) conducted a case study
of three patients who were diagnosed with Fibromyalgia (FMS)
and also found pain decreased with NFB.
Later research examined larger cohorts of patients (Jensen
et al., 2008, 2013a, 2014; Stokes and Lappin, 2010) and found
promising findings. Jensen et al. (2007) conducted a study with
18 patients with complex regional pain syndrome and found
a statistically significant decrease in pain reported pre to post
training, with over half of participants reporting a clinically
meaningful decrease of >30% (Moore et al., 2013). Stokes and
Lappin (2010) and Jensen et al. (2013a, 2014) found similar
results, however, Jensen et al. (2013a) found their decrease in
pain was not clinically meaningful. In addition to single-arm
designs, some studies have included control comparison groups
(Kayiran et al., 2010; Caro and Winter, 2011; Hassan et al., 2015).
Kayiran et al. (2010) implemented an active control group and
Caro and Winter (2011) implemented an historic control group,
and both found that their NFB groups demonstrated greater
success than the control group for pain reduction. Hassan et al.
(2015) attempted a placebo style control group, however, they
did not have a dedicated control group and instead applied
a sham style procedure to the 10th and 20th session for the
same participants. The challenges of a cross over control design
means that the participants will have possibly already learnt NFB
and it isn’t an isolated controlled condition and the training
they received previously may still influence how they respond
during the non-trained session. However, Hassan et al. (2015)
found promising findings with decreases in pain noted for the
NFB sessions, and no reported decrease in pain for the sham
conditions. All studies found results that offered support for the
efficacy of NFB with EEG, however, it was recommended further
controlled studies were required.
Importantly, the majority of these supporting studies lack
an optimal placebo control groups and only a few studies
have assessed whether cortical regulation (the key putative
mechanism) has actually occurred Roy et al. (2020). Rogala
et al. (2016) identified little evidence for desired changes in
EEG frequency power. Some studies have found pain changed
regardless of whether changes in EEG activity occurred (Jensen
et al., 2013b). A sham-control group is the most appropriate
research design to study a NFB intervention as it provides
a method of controlling for several components that are
fundamentally unrelated to EEG regulation but may nevertheless
affect pain or EEG (Schabus et al., 2017; Roy et al., 2020),
including attention and expectancy effects (Loo and Barkley,
2005, Thompson et al., 2011). If distraction, for example, is a
key putative mechanism that underlies any analgesic effects of
NFB treatment, it might be possible that such effects could be
more simply and easily achieved using a simple distraction task
(Thompson et al., 2011).
Most studies of NFB and pain have used protocols that
focus on regulation of EEG activity at a target site expected to
reflect cortical activity at key areas of the “pain matrix.” Imaging
studies have established that the anterior cingulate, insular,
primary/secondary cortices and the thalamus are active during
naturally occurring and experimentally induced pain, with
additional involvement of the prefrontal cortex in chronic pain
reflecting it’s greater cognitive-emotional component (Apkarian
et al., 2005). The variation of areas involved in pain processing
is mimicked by considerable variation in the protocols used in
previous studies. These have ranged from up-regulation of SMR
at C4 (Kayiran et al., 2010) and theta at AFz (Jensen et al., 2018) to
down-regulation of theta at Cz (Caro and Winter, 2011) or C2-C4
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(Vučković et al., 2019), with details not reported in several other
studies (Roy et al., 2020). A recent systematic review published
in this Frontiers Research Topic (Roy et al., 2020) provides an
extensive review of these protocols and concludes that no two
protocols used across the examined studies were identical.
Most commonly, studies of NFB and pain have used a
single fixed protocol applied to all participants. While such a
generalized approach would be expected to be most beneficial
for conditions with a predictable and homogenous pattern of
EEG activity, a more effective approach where heterogeneity
is present may be the use of individualized protocols based
on the pattern of EEG dysregulation for that individual. Such
data-driven protocols are typically based on an individual initial
quantitative electroencephalogram (qEEG) assessment, which is
compared to EEG from a normative database to identify the
electrode positions and bandwidths to be targeted with the
overarching aim of “normalizing” brain activity (Roy et al., 2020).
This approach has recently been successfully adopted in NFB
therapy for Chronic Tinnitus (Güntensperger et al., 2019) and
ADHD (Dobrakowski and Łebecka, 2020). Despite the existence
of an established cortical pain matrix, variation in EEG activity at
different frequency bands and scalp sites is still likely as a result of
heterogenous pain aetiology and individual factors such as head
shape, and a few studies have utilized individualized protocols.
Jensen et al. (2007), for example, used initial SMR up-regulation
at T3/T4 in individuals with Complex Regional Pain Syndrome,
but then employed progressively different protocols if the patient
failed to report improvement until an optimal individual protocol
was found. Prinsloo et al. (2018) used patient-specific protocols
and found NFB to reduce pain in cancer survivors (although the
authors did not report details of the electrode sites or frequencies
that were trained).
In the current study, we will examine the effect of NFB within
an experimentally induced cold pain paradigm applied to healthy
participants. This approach has the advantage of facilitating
the identification of an individualized protocol by comparing
each participant’s EEG during a pain-free state with their EEG
during noxious stimulation to identify the most relevant target
site and frequency band. The use of experimentally induced
pain also offers a level of control that can help overcome some
of the difficulties encountered in clinical settings, such as day-
to-day variation in chronic pain and use of pain medications
that can complicate interpretation (Staahl et al., 2009). The two
primary aims of the current study are to assess the ability of NFB
to: (1) modulate cortical activity during pain; and (2) produce
reductions in pain that exceed those of a sham-control group.
MATERIALS AND METHODS
Participants
The sample consisted of 24 healthy volunteers with a mean age of
27.9 years (SD = 12.3, range = 18–56) with 9 males and 15 females.
There was a mixture of 11 students (from the hosting University)
and 13 non-student volunteers. Students were compensated
with course credit for their participation, non-students were
volunteers who received no payment or compensation for their
time. Participants were required to confirm they did not violate
any of the exclusion criteria, which were any long-term pain
condition, Raynaud’s disease or any other condition that might
affect the perception of or cause an adverse reaction to pain.
Participants were also requested to abstain from the following
prior to experimentation to prevent potential disruption of pain
processing or EEG activity: analgesics (48 h); alcohol (12 h);
caffeine (2 h); and nicotine (1 h). Participants were asked if they
had ever taken part in a cold pain experiment or an experiment
with EEG. All participants (n = 24) stated that they had not.
Participants were assigned to either the sham control group
(n = 12) or the NFB group (n = 12) using block randomization
to ensure equal group sizes. Participants were aware that they
may be allocated to either the NFB or the placebo group but
were blinded to group assignment until the end of the study. The
researcher was not blinded as this was part of doctoral research
and therefore it was the same researcher designing the study and
implementing the research and analysis. Despite randomization
of participants there was some difference between groups in the
distribution of sex and age, with more females in the placebo
group (n = 9) than the NFB group (n = 6), and with a lower mean
age for the placebo (22 years) relative to the NFB group (31 years).
As only healthy participants were used no “standard of care”
equivalent was possible, however for all baselines the participants
not in pain data was used as a baseline to both inform protocol
selection and to set the target threshold for the NFB protocols.
Sham Control Group
The sham-control group and the NFB intervention group
underwent identical procedures, including assessment of
individualized training sites for their NFB training (see section
“Individualized Neurofeedback Protocols”), except for the
feedback provided to them during the session. Specifically, the
NFB intervention group were presented with genuine real time
EEG activity and the sham-control group were given false EEG
feedback using pre-recorded EEG data from participants who
had undergone genuine NFB training.
Pain Induction and Assessment
For pain induction, we employed the cold pressor task.
A thermostatically controlled tank was used, which housed
a circulating motor that ensured the water was consistently
and continuously circulated around the tank to avoid localized
heating of the hand. This method of pain induction is simple
to administer with no long-term adverse effects (Mitchell et al.,
2004). Further to this, the cold pressor test scores high in terms of
validity and is widely used across several research areas to induce
pain (Rebbeck et al., 2015). As shown in Figure 1, 3 × 4 min cold
water pain inductions were administered within each session of
NFB. Participants were told to take their hand out of the water at
any point if they found the pain unbearable.
For pain assessment, a 0–10 numerical rating scale (NRS)
was used to assess pain in response to cold stimulation and
was administered at multiple time points during each NFB
session. Specifically, participants were asked to verbally report
pain ratings at 15 s (for a baseline measure) and at 2, 3, and
4 min during each of the three 4-min cold trials that took place
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FIGURE 1 | Procedure for the initial qEEG session to identify individual training protocols to be used in subsequent NFB sessions.
FIGURE 2 | Flow chart of the procedure for an individual session, with NFB or sham given during the 3 pain tasks provided.
during each session, for a total of 12 ratings per session (see
Figure 2). The NRS is a well-established pain measure with a low
administration time of just a few seconds, which was necessary
to minimize disruption during the NFB session. For the purposes
of analysis, NRS pain scores were averaged across the 3 trials that
occurred with a session to produce a single pain rating at each of
15 s, 2, 3, and 4 min intervals.
Individualized Neurofeedback Protocols
To inform electrode placement for the individualized sessions,
a full brain EEG was first performed during a 4-min baseline
warm (37◦C) followed by a 4-min noxious cold (initially 10◦C)
trial, with this procedure conducted three times (Figure 1). The
purpose of this was to identify optimal training electrode sites
which best reflect changes in EEG during pain by comparing the
individual’s EEG activity (amplitude) when in pain, subject to
cold thermal noxious stimulation, and when not in pain (qEEG).
For EEG recording, we used a Mitsar 202-32 EEG amplifier
(REF), which has 31 active channels and 1 reference channel.
Electrodes were placed according to the extended 10–20 system
(channels included were: FPz, FP1, FP2, F7, F3, Fz, F4, F8, FT7,
FC3, FCz, FC4, FT8, T3, C3, Cz, C4, T4, TP7, CP3, CPz, CP4,
TP8, T5, P3, Pz, P4, T6, O1, Oz, O2; Thompson et al., 2008)
and EEG recorded at 256 Hz, with all electrode impedances
maintained at < 5 k throughout. A common reference of the
average signal across both ears was used during EEG acquisition.
After removal of EEG artifact, peak amplitude was computed
for the painful cold and the non-painful warm condition for
each electrode, for each of the three 8-min trials. The electrode
site and frequency band for NFB training for a participant was
selected based on the placement site for each individual and
frequency that appeared to demonstrate the largest amplitude
difference between the painful and non-painful stimuli, whilst
also demonstrating consistency across the three trials. This is a
similar method implemented by Stokes and Lappin (2010) who
collected data from 10 sites to determine peak amplitudes and
used this information along with prior experience to determine
5 homologous protocols to target their feedback. See Table 1 for
the final protocols used.
Cold Pressor Temperature Calibration
A single fixed noxious cold temperature can produce a wide
variation in subjective pain intensity (Graven-Nielsen et al.,
2001) and may produce no pain in some participants and
pain that cannot be tolerated for more than a short period
in others, we used an individualized temperature to provide a
relatively homogenous level of baseline pain across participants.
Specifically, we used a stimulus intensity that was tolerable for
that individual for 4 min (the duration of the pain stimulus) and
that resulted in a rating of 4–6 on a 0–10 pain rating scale as
this roughly approximates a moderate and clinically meaningful
level of pain (Boonstra et al., 2016). For the first trial, a 10◦C
temperature was initially used. If a pain rating <4 was given,
the procedure was repeated with a 1◦C reduction in temperature
(i.e., made colder), to make the task more painful, and was
continued until a 4–6 pain rating was reported. If the trial was
terminated before the 4 min had elapsed or pain ratings were
> 6, the temperature was increased by 1◦C in a subsequent trial.
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TABLE 1 | Protocols identified as optimal for the intervention and the (untrained)
sham control groups.
Group Frequency Direction Target site
NFB Alpha Up Pz
NFB Theta Up Fpz
NFB Alpha Up C4
NFB Alpha Up Pz
NFB Theta Down Pz
NFB Alpha Up FCz
NFB Theta Down Cz
NFB Alpha Up Pz
NFB Theta Up FCz
NFB Theta Up FCz
NFB Theta Up Fz
NFB Alpha Down C3
Control Alpha Down CP3
Control Alpha Up Pz
Control Alpha Up Fp1
Control Alpha Up P4
Control Alpha Up Pz
Control Alpha Up C3
Control Alpha Down Cp3
Control Theta Down F4
Control Alpha Up Cp3
Control Alpha Down C4
Control Alpha Up T3
Control Alpha Down FCz
The final individual temperature reached was applied for that
participant in all the following NFB sessions. A comparison of
NFB experimental and sham control groups with independent
t-tests found no group differences in either temperature [t = 0.65,
p = 0.52, M (NFB) = 10.2◦C, M (Sham) = 9.8◦C] or baseline pain
intensity [t = 0.04, p = 0.97, M (NFB) = 4.52, M (Sham) = 4.54].
The entire first session took between 90 and 120 min to
complete. This included time to brief and debrief, set up the
equipment, and conduct assessments and the trials. Participants
were also shown their EEG and the experimenter explained
the implications of artifacts and showed how they are caused
and how to avoid them to help reduce avoidable artifacts
(Thompson et al., 2008).
Neurofeedback
NFB was performed using a Nexus-4, which has up to 2 EEG
channels recorded at a sampling rate of 256 Hz. Electrode
placement was determined by an individual assessment of each
participant’s EEG during pain as previously described (see section
“Individualized Neurofeedback Protocols”). Biotrace software
was used for the application of the NFB protocol and to build the
biofeedback screen used (Figure 3 provides a screenshot). The
reward protocol was to feedback a reward to the participant of
1 point for every second they were able to maintain their EEG
within the targeted range.
The threshold (target) for the NFB protocol was calculated
by recording 4 min of eyes open activity using the feedback
electrode. The participants were not subject to any pain, but
their hand was immersed into warm water as done above for
the first baseline to identify the NFB protocol. This was to
give a target to reinforce that was related to the subject non
pain state on that day and at that time. The average EEG
amplitude from the 4-min was used. This was repeated at the
start of every NFB session to account for variations (e.g., different
times of day) and the same threshold was used for all three
trials within that session. This baseline was recorded with the
participant’s non-dominant hand immersed into the warm water.
This identified what their normal frequency for the targeted
protocol frequency was for that electrode site when not in pain
and was the benchmark for which they are attempting to train
their cortical activity to return to during training. In addition
to the training protocol, an EMG (muscle/movement artifact)
control was added to the NFB screen to encourage participants
to keep their EMG artifact low. The inhibit EMG bar was
displayed to the left of the NFB protocol and showed green
when the participant kept this at the correct level, and red when
EMG increased. To further encourage participants to keep their
EMG low, participants would only achieve points/rewards for
achieving their protocol when their EMG was also at the correct
level. This control helped to prevent moving, EMG artifact,
and participants from training themselves to move to achieve
the NFB protocol.
Participants took part in 10 NFB sessions, which were
conducted 3–7 times per week subject to participants’ availability,
with no more than one session per day to avoid fatigue
but to ensure it was regular. Each session lasted around 45–
60 min, which included set up time, briefing/debriefing, baseline
measurement and three cold trials (Figure 2). Each session
consisted of 3 × 4 min cold pain tasks at the participant’s
individualized temperature.
In the first of the ten NFB sessions, participants were given a
minute to practice and understand the objective of the session.
Participants were not provided with a strategy, only to be
observant of when their cortical activity fed back that they had
been successful and to try to replicate that. Their understanding
was checked, and they were reminded about artifacts and how
to avoid them. In each of the 4-min cold trials, pain ratings were
recorded at 15 s, 2, 3, and 4 min or when they removed their hand.
A break of up to 5 min was added in between each cold pain task
in order to allow participants to recover from the numbing effects
of the cold water.
EEG Data Pre-processing
The data was visually inspected and if any large EMG artifacts
were found these were removed manually before running
independent component analysis (ICA) to identify EOG artifact.
ICA was conducted using the WinEEG software with eye blink
or lateral eye movement components removed automatically
(Gao et al., 2010).
In the initial assessment of data for determining protocols,
WinEEG was used to conduct Fast Fourier Transform (FFT)
for Delta (0–4 Hz), Theta (4–8 Hz), Alpha (8–12 Hz), and Beta
(12–40 Hz), visually comparing all spectral output (with a similar
approach to Stokes and Lappin, 2010), by subtracting the baseline
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FIGURE 3 | Screenshot of NFB screen presented during NFB/sham. EMG inhibit bar encouraged participants to keep their movement artifact low, and to prevent
conditioning participants to achieve the desired outcome through movement. This second column shows an alpha uptraining example. However, alpha up, alpha
down, theta up, and theta down were all protocols used in this study.
from the painful condition. For the main analysis, amplitudes
for the target frequency bands (alpha or theta) were computed
using FFT from the first 30 s and the last 30 s for each of the
three trials within a session. These were then averaged across the
three trials, at each time point within a session, to give a single
mean amplitude for the first 30 s and the last 30 s of each of
the 10 sessions.
Statistical Analysis Plan
The Effect of Neurofeedback on Pain and Regulation
of EEG
Mixed ANOVAs were used to examine whether changes in EEG
occurred during sessions (first 30 s vs. last 30 s) and across
sessions (1–10), and whether this differed by group (NFB vs.
control). Given that the target EEG amplitude (established from
the individual’s EEG activity during their pain-free baseline
state) required up-regulation for some participants and down-
regulation for others, change was coded such that a positive
sign indicated a change in the desired direction (i.e., toward the
target amplitude) while a negative sign indicated a change in the
opposite direction. Although there are different ways in which
training “success” could be potentially assessed, we computed the
size of the difference between the participant’s target amplitude
and the amplitude during the pain task (at the chosen training
site and frequency band). Smaller differences therefore represent
greater “success,” as reward protocols were designed to return
amplitude to the target frequency associated with a baseline
pain-free state.
To assess whether NFB resulted in lower pain than the control
procedure during sessions (baseline 15 s, 2, 3, and 4 min)
or across sessions (1–10), the same analysis was conducted as
described above, but with pain ratings as the outcome variable.
In all instances, trend analysis was also conducted to examine
whether any progressive changes in EEG or pain across sessions
followed a linear or quadratic trend.
RESULTS
Data Screening
EEG data were missing for 5 of the 240 (2%) sessions due to
equipment failure, and these values were imputed using the
mean value from non-missing participants for the equivalent
trial and session number. For pain rating data, < 2% of data
were missing so we imputed missing values with the participant’s
trial average. No outliers were identified (z > 3.29 or < −3.29,
Tabachnick and Fidell, 2013) for pain ratings. Z scores for EEG
amplitudes suggested 5 outliers which were again substituted
with linear interpolations of that participant’s adjacent sessions.
Alpha (SD = 2.9) and theta (SD = 2.1) frequencies showed
similar dispersion.
Regulation of EEG
Individual protocols for each participant in the NFB groups are
shown in Table 1 (which also shows the protocols identified to
be optimal for the sham-control participants although no actual
NFB was performed). Training protocols for the NFB group
consisted of a mixture of alpha and theta training (at different
electrode sites), with six participants receiving alpha training
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(down-regulation = 1, up-regulation = 5) and six receiving theta
regulation (down-regulation = 2, up-regulation = 4).
ANOVA revealed a significant overall deviation from target
EEG during a session [F(1, 22) = 10.35, p = 0.004], with this
deviation greater during the first 30 s (M = 3.01) compared to the
last 30 s (M = 2.08) of the pain task. There was also a significant
During-session X Group interaction [F(1, 22) = 10.31, p = 0.004],
with Figure 4 suggesting EEG amplitude was closer to the target
value during NFB than the control procedure during the first 30 s
of the pain task, but with little difference near the end of the task.
No other effects approached significance (p = 0.13–0.46), with all
results shown in Table 2.
As different protocols were used, we conducted an exploratory
investigation of whether alpha training or theta training
produced a greater impact on EEG parameters by rerunning
ANOVA on the NFB experimental group only (a protocol was
not implemented for the sham group), but including frequency
band (alpha vs. theta) as an additional variable. Results found no
significant differences between alpha (M = 2.06 µV) and theta
(M = 2.24 µV) frequency bands (p = 0.798) or any interactive
effects (p = 0.342–0.813). We did not compare up-regulation
(M = 2.35 µV) vs. down-regulation (M = 1.55 µV) with
inferential statistical tests given the fact only three participants
were given down-regulation training.
Pain Modulation
ANOVA revealed a significant difference in mean pain ratings
during the session F(3, 66) = 7.34, p < 0.001), with Figure 5
showing a sharp rise in pain from 15 s to that at 2, 3, and 4
min period, with a quadratic trend identified [F(1, 22) = 24.31,
p < 0.001]. Neither the control nor the experimental groups saw
a clinically meaningful reduction in average pain ratings (>30%).
With respect to changes in overall pain across sessions,
significant differences across the 10 sessions were also observed
[F(9, 198) = 3.09, p = 0.002], with trend analysis indicating
a progressive linear decrease in pain overall across sessions
[F(1, 22) = 6.91, p = 0.015]. There was no significant interaction
of during session changes and group, with both NFB and controls
demonstrating a similar decrease in pain ratings across sessions
as shown in Figure 6. Table 3 shows the complete table of results
and with no other effects significant.
TABLE 2 | Results of the Mixed ANOVA for EEG amplitude with η2 indicating the
partial-eta squared effect size.
df F η2 p-value
Group 1, 22 2.39 0.098 0.137
Acrossa sessions 5.8, 127.9 0.96 0.042 0.455
Duringb session 1, 22 10.35 0.320 0.004*
Group × Across sessions 5.8, 127.9 1.67 0.071 0.135
Group × During session 1, 22 10.31 0.319 0.004*
Across sessions × During session 6.2, 136.9 0.98 0.043 0.441
Group × Across sessions × During session 6.2, 136.9 1.38 0.059 0.226
aAcross sessions (1–10).
bDuring a session (first 30 vs. last 30 s). *Significant <0.05.
TABLE 3 | Results of the Mixed ANOVA for pain ratings with η2 indicating the
partial-eta squared effect size.
df F η2 p-value
Group 1, 22 0.23 0.010 0.637
Acrossa sessions 9, 198 3.09 0.123 0.002*
Duringb session 3, 66 7.34 0.250 < 0.001*
Group × Across sessions 9, 198 0.43 0.019 0.919
Group × During session 3, 66 0.92 0.040 0.437
Across sessions × During session 27, 594 01.45 0.062 0.069
Group × Across sessions × During session 27, 594 0.73 0.032 0.838
aAcross sessions (1–10).
bDuring a session (baseline 15 s, 2, 3, and 4 min). *Significant <0.05.
We also conducted an exploratory investigation of whether
pain ratings were impacted by the type of frequency band trained
(alpha vs. theta) as described in the previous section. Results
indicated no main (p = 0.853) or interactive effect of frequency
band on pain ratings (p = 0.315–0.699).
DISCUSSION
Several key results emerged from the present study. First,
although we individualized neurofeedback protocols based on
each participant’s EEG response to painful stimulation, a general
pattern of altered EEG activity in certain regions of the scalp
at specific frequency bands emerged. In particular, alterations
in alpha and theta frequency bands in mostly frontal, and
some central, regions were observed, suggesting these may be
key target areas for NFB for pain management. This is largely
consistent with cortical areas found to be active during pain
in imaging studies (Apkarian et al., 2005, 2009; Fitzgerald,
2020), but also supports the complex nature of pain and the
need to better understand the relationship between the brain
and pain on a cortical level (EEG) to develop efficacious NFB
protocols with EEG.
Second, in terms of the ability of participants to regulate EEG
activity when in pain, results indicated EEG amplitude at the
training site during pain was closer to the target amplitude for
the NFB than the sham group in the early stages of the pain task.
Importantly, however, this was only observed during the first 30
s of the training task, with no differences between NFB and sham
in the latter stages of the task (final 30 s). This pattern of results
does not provide a clear-cut picture of whether EEG regulation
during pain is possible. One possible interpretation is that EEG
can be more successfully regulated (compared to the natural EEG
occurs during pain) during the early stages of pain, but that
this becomes more difficult after sustained exposure to noxious
stimulation. However, it seems unlikely that any substantive
training effects would be present so early on in the task (30 s),
and any differences at this stage of the task seem more likely to
simply reflect group differences in reaction to an initial noxious
stimulus. This ambiguous pattern of findings does little to resolve
the question of whether EEG can be regulated during pain, but
does underline the complex nature of EEG changes that occur
during pain and clearly indicates that more convincing evidence
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FIGURE 4 | Mean absolute deviation from baseline EEG amplitude for NFB and sham control groups during the first 30 and last 30 s of the pain tasks (error bars
represent ± 1 SE).
FIGURE 5 | Mean pain rating at different stages of the 4-min pain trial for NFB and sham control groups (error bars represent ± 1 SE).
is required before this claims that EEG can be regulated during
pain can be made.
These findings are consistent with some previous work.
Hassan et al. (2015) reported that in control sessions of NFB,
changes in power spectral density (PSD) did not differ across
the placebo controlled condition to before the session (pre-NFB
vs. during NFB), suggesting that training did not take place
in the controlled condition; however, there doesn’t appear to
be a direct comparison between groups to test for statistical
significance. Kayiran et al. (2010) identified no significant
changes in EEG amplitude overall, however, they identified a
statistically significant difference for session 4. This suggests that
further research is needed to better understand this, for example
Aliño et al. (2016) and Roy et al. (2020) suggest additional
variations of sham-procedures that could be run in parallel with
an intervention to further study changes between intervention
and sham groups, as well as double blinding (Ros et al., 2020),
which future research could attempt with pain. Overall, these
results are consistent with the possibility that NFB can elicit
changes in EEG during pain that are different from those that
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FIGURE 6 | Mean pain rating across sessions for NFB and sham control groups (error bars represent ± 1 SE).
occur with a sham procedure, although the fact that this seemed
to occur only in the early stages of noxious stimulation does
underline the need for further corroborating evidence.
With respect to the potential for NFB as a technique for
pain management, we found no differences in pain ratings
between NFB and sham control either during the sessions or
across sessions. We did, however, find a decrease in average pain
intensity with progressive sessions that were very similar for
both the NFB and sham control groups. This could provocatively
suggest that any putatively beneficial effects on pain before and
after a series of NFB session observed in previous studies that
do not provide a sham comparator may have been attributable
simply to non-EEG regulatory mechanisms such as placebo
expectation effects, demand characteristics or a number of other
potential explanations (Loo and Barkley, 2005; Thompson et al.,
2011; Gollub et al., 2018).
Although our study involved experimentally induced pain
in healthy participants, rather than clinical pain, these findings
do nevertheless demonstrate that changes in reported pain can
occur in the absence of real NFB and this may be critical to the
interpretation of any possible therapeutic effects. There appears
to be little previous research that has compared changes in
pain during NFB to a sham procedure, and the current findings
endorse the view of Aliño et al. (2016) that a suitable sham
procedure is essential to identify any clear benefits of NFB. One
study by Hassan et al. (2015) has attempted to test for a placebo
effect in two ways. One involved displaying a pre-recorded NFB
session and the other involved displaying visual feedback and
targeting Oz (the occipital area), which is not normally associated
with pain. This was done on the 10th and 20th training session for
participants so there was no independent sham-control group. As
mentioned previously this limitation means that learning or other
carryover effects cannot be ruled out. Hassan et al. (2015) found
that the targeted activity for participants did not change in the
placebo-controlled group studying PSD, nor was a reduction in
pain reported. The alpha placebo control did note a shift in alpha,
but again no change in pain reported. Although these findings
seem promising, this design does not allow conclusions of the
efficacy of NFB to be made and further controlled studies were
required. This study has attempted to address this and is able
to make direct comparisons between a sham-control group and
a NFB intervention group, including a manipulation check to
not only study if EEG changed, but if it was changing as was
intended/trained.
The current study has several limitations. First, it is impossible
to say from our results whether NFB per se is ineffective for
reducing pain, or simply that there is limited evidence for the
effectiveness of the NFB approach we examined. Given the almost
endless variation in how neurofeedback can be administered
(e.g., a differing number and length of sessions, single or
multiple channel approaches, outcomes targeted, different reward
protocols etc.), it would be unwise to dismiss the possibility of
therapeutic effects of NFB. Given encouraging findings reported
elsewhere, further work is clearly required to identify which
of these factors might be important in potentially affecting
the success of NFB. Second, while the use of an experimental
pain paradigm offers a high degree of control, results do not
necessarily generalize to clinical pain which differs on intensity,
perceived control and frontal cortex involvement (Apkarian
et al., 2005). Despite this, there are many cortical areas that are
commonly active during the processing of both chronic and acute
pain and therefore does have the potential to be effective, these
findings suggest that the most likely target is the frontal and
central areas area (e.g., FCz, Pz). Third, if a genuine analgesic
effect of NFB does exist, it may simply have been that the current
study was underpowered to detect this. As there are few if any
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studies that have examined the impact of NFB on experimentally
induced pain we were not able to estimate an effect size that
could be used a priori to perform power analysis calculations.
Although the p-value for pain indicated a reliable decrease in pain
ratings across sessions (p = 0.015) and the present sample size is
similar to others in the field, a larger sample size in future could
provide greater power for group comparisons. Fourth, despite
random group allocation there were some chance differences
in age and gender across groups, with the NFB group 9 years
older on average with more females compared to the sham
group (9 vs. 6). As we examined NFB effects within a repeated-
measures design, we would not expect these differences to have
had any substantive impact on an evaluation of therapeutic
effects, in the absence of any previous robust evidence of
any major moderating effects of these variables. Nevertheless,
stratification may be a sensible option in future studies to
avoid this possibility given it is often difficult to recruit large
numbers of people in NFB studies needed for randomization to
be most effective.
Overall, these findings underline the importance of a robust
study design which includes an appropriate sham control group
in order to reliably evaluate the possible therapeutic effects of
NFB. In particular, the fact that an analysis of the NFB group
in isolation would have indicated a successful reduction in
pain across progressive sessions and thus a treatment benefit,
despite a similar benefit being observed in the sham group,
does prompt extreme caution in interpreting previous studies
indicating NFB benefits where no sham control group is present.
Further studies including those with clinical pain populations
that include an appropriately designed sham control group
are needed to clarify the therapeutic potential for NFB as a
pain intervention.
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